U.S. Professional Services Stock News

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

NasdaqCM:NCTY 1 Year Share Price vs Fair Value Explore The9's Fair Values from the Community and select yours To the...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

NYSE:CCL 1 Year Share Price vs Fair Value Explore Carnival Corporation &'s Fair Values from the Community and select...

In recent days, NICE announced an expanded partnership with Salesforce to deliver seamless, AI-driven customer experiences through a deeper integration between NICE CXone Mpower and Salesforce Service Cloud, including plans to join the Salesforce Zero Copy Partner Network for a unified data foundation. This collaboration aims to break down data silos and empower real-time, AI-driven orchestration across both platforms for hundreds of thousands of shared users, highlighting Salesforce’s focus...

Syndax Pharmaceuticals recently reported second quarter 2025 results, showing revenues of US$37.96 million, up sharply from US$3.5 million a year earlier, and a net loss of US$71.85 million, compared with US$68.06 million previously. Alongside this earnings release, the company announced that the FDA has granted Priority Review for Revuforj’s supplemental New Drug Application in relapsed or refractory mutant NPM1 acute myeloid leukemia, highlighting expanding opportunities in its targeted...

Simon Property Group recently reported second quarter earnings showing increased revenue and net income, alongside raising its common stock dividend to US$2.15 for the third quarter and updating its annual earnings guidance. Among new initiatives, Humana announced a collaboration with Simon to launch health and community programs in 21 Simon centers, highlighting Simon's growing role as a destination for experiential retail and community engagement. We'll explore how Simon's latest earnings...

Earlier this month, Revvity unveiled its pHSense™ reagents, a new technology developed to improve the efficiency and accuracy of internalization studies in drug discovery, specifically for G protein-coupled receptors (GPCRs) and antibody-drug conjugates (ADCs). This platform aims to address current challenges in high-throughput screening and is positioned to meet rising demand for advanced tools in oncology and precision medicine research workflows. We'll examine how the launch of pHSense™...

Celldex Therapeutics reported its second quarter 2025 earnings, revealing US$730,000 in revenue and a net loss of US$56.6 million, both materially weaker than the previous year's results for the same period. Revenue fell sharply year-over-year while net losses widened, highlighting increased operating challenges for the company during the first half of 2025. We'll examine how the combination of lower revenue and growing losses shapes Celldex's investment narrative and financial outlook. Find...

Earlier this month, MarketAxess Holdings reported strong second quarter results with revenue rising to US$219.46 million and multiple enhancements to its electronic trading protocols, while also announcing a quarterly dividend and signaling readiness for merger and acquisition opportunities. CEO Christopher Concannon highlighted both a robust balance sheet and new executive capacity as key enablers for potential M&A, suggesting an active approach to future growth initiatives beyond...

Structure Therapeutics Inc. recently reported a second-quarter net loss of US$61.66 million, widening from US$26.03 million a year ago, and for the six-month period, the net loss also increased to US$108.49 million from US$52.07 million in the previous year. Following these results, the company filed for a US$250 million follow-on equity offering and a shelf registration allowing future issuance of various securities including American Depositary Shares, preferred shares, debt securities,...

Yum! Brands, Inc. reported its second quarter 2025 earnings on August 5, revealing US$1.93 billion in revenue and US$374 million in net income, both higher than the same period last year. While the quarter showed stronger sales, net income for the first half of 2025 was US$628 million, down from US$681 million a year earlier, reflecting mixed profitability trends despite revenue growth. We'll now explore how these mixed profit and revenue results may affect Yum! Brands' ongoing investment...

In August 2025, Crocs, Inc. reported second-quarter earnings that included sales of US$1,149.37 million but a net loss of US$492.28 million, and provided guidance for a 9% to 11% revenue decrease in the third quarter compared to the previous year. Alongside ongoing share repurchases totaling over US$2.58 billion since 2013, Crocs faced a significant swing to quarterly losses and signaled softer demand ahead. We'll now examine how Crocs' weaker third quarter revenue outlook impacts its...

Earlier this month, Quanta Services completed a US$1.5 billion multi-tranche senior notes offering with maturities spanning 2028, 2031, and 2035, intending to use the proceeds to repay existing borrowings under its commercial paper program and senior credit facility. By extending its debt maturity profile and locking in fixed interest rates, Quanta Services could see changes in its financial flexibility and interest expenses, influencing its future capital allocation decisions. We'll explore...

Recursion Pharmaceuticals, Inc. recently reported its second quarter 2025 results, revealing revenue of US$19.22 million with a net loss of US$171.9 million, and announced its presentation at the 7th Annual Ai4 2025 conference in Las Vegas by VP of Product, Erik Douglas. While the company achieved higher revenue year over year, its net losses grew substantially, highlighting the ongoing challenge of translating innovation-driven growth into profitability. To better understand the company's...

Ondas Holdings Inc. recently completed a follow-on equity offering of US$150.02 million, issuing 46,160,000 shares at US$3.25 each, following its second quarter earnings report which showed a large jump in sales but continued net losses. The company also reaffirmed its full-year revenue guidance of at least US$25 million for 2025, highlighting a focus on growth despite ongoing profitability challenges. We'll assess how Ondas Holdings' substantial capital raise could influence its evolving...

Lucid Group recently announced a collaboration with Uber Technologies and Nuro to develop and deploy next-generation premium robotaxis on Uber’s ride-hailing platform, with Uber investing US$300 million and planning to roll out at least 20,000 Lucid Gravity vehicles equipped with Nuro autonomy over six years in global markets. This partnership positions Uber to accelerate its efforts in autonomous mobility and underscores its intent to compete in the rapidly evolving robotaxi sector through...

Earlier this month, MakeMyTrip announced the launch of a GenAI-enabled Trip Planning Assistant, enhancing travel planning with voice and text support in English and Hindi, and expanding soon to additional Indian languages. This upgrade aims to bridge the gap for non-English speakers in India by enabling conversational travel bookings from inspiration to completion, setting MakeMyTrip apart from many global peers that stop at recommendations. Next, we’ll examine how this expansion of...

TG Therapeutics recently reported strong second quarter results, with US$141.15 million in revenue and a sharp rise in net income, and raised its full-year 2025 revenue guidance to approximately US$585 million. The company also filed multiple shelf registrations totaling up to US$139.45 million, including an ESOP-related offering, indicating preparations for potential future capital needs alongside improving financial performance. We’ll now explore how the raised annual guidance and robust...

Fastly announced its second-quarter 2025 earnings, updated guidance, key executive appointments, including a new CFO, and a shelf registration for US$12.76 million in Class A shares for an employee stock plan. The consolidation of marketing and revenue under a new President, alongside leadership changes and fresh capital strategies, marks an important expansion of operational focus and corporate direction. We'll explore how Fastly's leadership realignment and updated guidance may influence...

GRAIL, Inc. reported second quarter and six-month results for the period ended June 30, 2025, showing sales of US$34.38 million and US$63.51 million respectively, with net losses narrowing substantially from the prior year and impairment charges decreasing to US$28 million from a very large US$1.42 billion a year earlier. This sharp reduction in both net loss and impairment charges points to improved operational discipline and financial stability at the company. We'll explore how GRAIL's...

IHS Holding Limited recently reported a shift to net profit for the second quarter and first half of 2025, alongside revising its full-year 2025 revenue guidance upward to US$1.70 billion–US$1.73 billion. This turnaround in earnings performance marks a departure from significant net losses in the previous year, highlighting ongoing improvements in operational efficiency and revenue quality. We will examine how IHS Holding's boosted revenue outlook and profitability transformation could...

Natera announced second quarter 2025 results, reporting revenue of US$546.6 million and expanding its annual revenue guidance by US$80 million, while also introducing Fetal Focus, a new noninvasive prenatal test for inherited conditions backed by clinical trial data. The addition of Fetal Focus addresses a key unmet need in prenatal testing, potentially strengthening Natera's competitive position and appeal with both physicians and patients. We'll explore how the launch of Fetal Focus and...

Earlier this past week, Kymera Therapeutics announced positive results from its first KT-621 clinical trial, which delivered strong efficacy and a placebo-like safety profile, alongside new collaborations with Gilead and Sanofi and disclosure of a cash reserve near US$1 billion by July's end. An important takeaway is that Kymera's strengthened pipeline through high-profile partnerships and a substantial cash runway may provide meaningful support for future research and development...